Cefpodoxime proxetil – new opportunities in antibacterial therapy of respiratory infections

Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(4):366-371

​ Avdeev S.N., Andreeva I.V., Gorelov A.V., Gurov A.V., Dekhnich A.V., Zyryanov S.K., Karpova E.P., Kozlov R.S., Leshchenko I.V., Ovchinnikov A.Yu., Rachina S.A., Ryazantsev S.V., Svistushkin V.M., Sinopalnikov A.I., Stetsiouk O.U.
10.36488/cmac.2023.4.366-371
Section
Antimicrobials
Type
Expert opinion
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(4):366-371

Abstract

The purpose of the expert council was to determine the place of cefpodoxime in the ABT algorithms for upper and lower respiratory tract infections and to form a consensus position on its use in clinical practice. Based on the available data, the possibility of including cefpodoxime in national guidelines for the treatment of rhinosinusitis, acute tonsillopharyngitis, community-acquired pneumonia (CAP), as well as infectious exacerbations of chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD) is being considered.

Sergey N. Avdeev

Federal State Autonomous Educational Institution of Higher Education “First Moscow State Medical University named after. THEM. Sechenov" of the Ministry of Health of Russia

Irina V. Andreeva

Research Institute of Antimicrobial Chemotherapy of the Federal State Budgetary Educational Institution of Higher Education "Smolensk State Medical University" of the Ministry of Health of Russia

Gorelov A.V.

Institute of Children's Health named after. N.F. Filatov
Federal State Autonomous Educational Institution of Higher Education “First Moscow State Medical University named after. THEM. Sechenov" of the Ministry of Health of Russia

Gurov A.V.

Federal State Autonomous Educational Institution of Higher Education “Russian National Research Medical University named after. N.I. Pirogov" of the Ministry of Health of Russia

Andrey V. Dekhnich

Research Institute of Antimicrobial Chemotherapy of the Federal State Budgetary Educational Institution of Higher Education "Smolensk State Medical University" of the Ministry of Health of Russia

Sergey K. Zyryanov

Federal State Autonomous Educational Institution of Higher Education "Russian Peoples' Friendship University"
GBUZ "City Clinical Hospital No. 24" of the Moscow Department of Health

Karpova E.P.

Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuing Professional Education" of the Ministry of Health of Russia

Roman S. Kozlov

Federal State Budgetary Educational Institution of Higher Education "Smolensk State Medical University" of the Ministry of Health of Russia

Leshchenko I.V.

Federal State Budgetary Educational Institution of Higher Education "Ural State Medical University" of the Ministry of Health of Russia

Ovchinnikov A.Yu.

Federal State Budgetary Educational Institution of Higher Education "Moscow State Medical and Dental University named after. A.I. Evdokimov" of the Ministry of Health of Russia

Svetlana A. Rachina

Federal State Autonomous Educational Institution of Higher Education “First Moscow State Medical University named after. THEM. Sechenov" of the Ministry of Health of Russia

Ryazantsev S.V.

Federal State Budgetary Educational Institution of Higher Education “North-Western State Medical University named after. I.I. Mechnikov" of the Ministry of Health of Russia
St. Petersburg Research Institute of Ear, Throat, Nose and Speech

Svistushkin V.M.

Federal State Autonomous Educational Institution of Higher Education “First Moscow State Medical University named after. THEM. Sechenov" of the Ministry of Health of Russia

Alexander I. Sinopalnikov

Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuing Professional Education" of the Ministry of Health of Russia

Olga U. Stetsiouk

Research Institute of Antimicrobial Chemotherapy of the Federal State Budgetary Educational Institution of Higher Education "Smolensk State Medical University" of the Ministry of Health of Russia

  • 1. The Lancet. Antimicrobial resistance: time to repurpose the Global Fund. Lancet. 2022;399(10322):335. DOI: 10.1016/S0140-6736(22)00091-5
  • 2. Ivanchik N.V., Chagaryan А.N., Sukhorukova М.V., Kozlov R.S., Dekhnich А.V., Krechikova О.I., et al. Antimicrobial resistance of clinical Streptococcus pneumoniae isolates in Russia: the results of multicenter epidemiological study «PEHASus 2014-2017». Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2019;21(3):230-237. Russian. DOI: 10.36488/cmac.2019.3.230-237
  • 3. On the use of antibacterial therapy in patients with a new coronavirus infection COVID-19. Terpevticheskij arhiv. 2020;11:4. Russian.
  • 4. Kuzmenkov A.Yu., Vinogradova A.G., Trushin I.V., Edelstein M.V., Avramenko A.A., Dekhnich A.V., Kozlov R.S. AMRmap – antibiotic resistance surveillance system in Russia. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2017;19(2):84-90. Russian. DOI: 10.36488/cmac.2021.2.198-204
  • 5. Vanderkooi O.G., Low D.E., Green K., Powis J.E., McGeer A.; Toronto Invasive Bacterial Disease Network. Predicting antimicrobial assistance in invasive pneumococcal infections. Clin Infect Dis. 2005;40(9):1288-1297. DOI: 10.1086/429242
  • 6. Harris A.M., Hicks L.A., Qaseem A.; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and prevention. Ann Intern Med. 2016;164:425-434. DOI: 10.7326/M15-1840
  • 7. Metlay J.P., Waterer G.W., Long A.C., Anzueto A., Brozek J., Crothers K., et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. DOI: 10.1164/rccm.201908-1581ST
  • 8. Balter M.S., La Forge J., Low D.E., Mandell L., Grossman R.F.; Canadian Thoracic Society; Canadian Infectious Disease Society. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J. 2003;10(Suppl. B):3B-32B. DOI: 10.1155/2003/486285
  • 9. Medscape. Bronchitis empiric therapy. Available at: http://emedicine.medscape.com/article/2012603-overview. Accessed May 23, 2023.
  • 10. Medscape. Acute rhinosinusitis empiric therapy. Available at: https://emedicine.medscape.com/article/2002860-overview. Accessed May 23, 2023.
  • 11. Stanford Antimicrobial Safety & Sustainability Program. SHC Cough Syndromic Antimicrobial Selection Guidelines. Available from: https://med.stanford.edu/content/dam/sm/bugsanddrugs/documents/outpatientASP/SHCOutpatient-Cough-Guide.pdf. Accessed May 23, 2023.
  • 12. Bauernfeind A., Jungwirth R. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil. Infection. 1991;19(5):353-362. DOI: 10.1007/bf01645369
  • 13. Gehanno P., Andrews J.M., Ichou F., Sultan E., Lenfant B. Concentrations of cefpodoxime in plasma and tonsillar tissue after a single oral dose of cefpodoxime proxetil. J Antimicrob Chemother. 1990;26(Suppl. E):47-51. DOI: 10.1093/jac/26.suppl_e.47
  • 14. Mason Jr. E.O., Lamberth L.B., Kershaw N.L., Prosser B.L., Zoe A, Ambrose PG. Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis. J Antimicrob Chemother 2000;45(5):623-631. DOI: 10.1093/jac/45.5.623
  • 15. Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC). Report on research work «Study of the activity of the drug cefpodoxime against bacterial pathogens of community acquired respiratory infections isolated from patients in different regions of the Russian Federation». Smolensk, 2023. Russian.
  • 16. Jones R.N., Zurenko G.E. Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result. Diagn Microbiol Infect Dis. 1993;17(4):313-316. DOI: 10.1016/0732-8893(93)90041-5
  • 17. Frampton J.E., Brogden R.N., Langtry H.D., Buckley M.M. Cefpodoxime proxetil: a review. Drugs. 1992;44(5):889-917. DOI: 10.2165/00003495-199244050-00011
  • 18. Ministry of Health of the Russian Federation. Clinical recommendations. Acute tonsillitis and pharyngitis (Acute tonsillopharyngitis). 2021. Available at: https://cr.minzdrav.gov.ru/recomend/306_2. Accessed October 01, 2023. Russian.
  • 19. Ministry of Health of the Russian Federation. Clinical recommendations. Acute sinusitis. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/313_2. Accessed October 01, 2023. Russian.
  • 20. Ministry of Health of the Russian Federation. Clinical recommendations. Chronic obstructive pulmonary disease. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/603_2. Accessed October 01, 2023. Russian.
  • 21. Ministry of Health of the Russian Federation. Clinical recommendations. Community acquired pneumonia in adults. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/654_1. Accessed October 01, 2023. Russian.
  • 22. Bergogne-Berezin E. Cefpodoxime proxetil in upper respiratory tract infections. Drugs. 1991;42(Suppl. 3):25-33. DOI: 10.2165/00003495-199100423-00007
  • 23. Portier H., Chavanet P., Gouyon J.B., Guetat F. Five-day treatment of pharyngotonsillitis with cefpodoxime proxetil. J Antimicrob Chemother. 1990;26(Suppl. E):79-85. DOI: 10.1093/jac/26.suppl_e.79
  • 24. Hamid O.A., Dokhan M., El Gamea A., Ahmed H.A., Feseekh N.T., El Deghedy M.A., Hussei M.A. Effectiveness and safety of cefpodoxime in upper respiratory tract infections in adult Egyptian population a report from the Egyptian STAR registry. Egyptian Journal of Ear, Nose, Throat and Allied Sciences. 2017;8(2):131-135. DOI: 10.1016/j.ejenta.2017.08.002
  • 25. Instructions for use of the medicinal product for medical use Doxef. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e7320a63-02b0-4a86b7ab-3a58d3841f81. Accessed October 01, 2023. Russian.
  • 26. Portier H., Chavanet P., Waldner-Combernoux A., Kisterman J.P., Grey P.C., Ichou F., Safran C. Five versus ten days treatment of streptococcal pharyngotonsillitis: a randomized controlled trial comparing cefpodoxime proxetil and phenoxymethyl penicillin. Scand J Infect Dis. 1994;26(1):59-66. DOI: 10.3109/00365549409008592
  • 27. Polonovski J.M., El Mellah M. Traitement des sinusites maxillaires aiguës de l'adulte. Efficacité et tolérance du cefpodoxime-proxétil versus amoxicilline-acide clavulanique [Treatment of acute maxillary sinusitis in adults. Comparison of cefpodoxime-proxetil and amoxicillinclavulanic acid]. Presse Med. 2006;35(1 Pt. 1):33-38. French. DOI: 10.1016/s0755-4982(06)74516-x
  • 28. Geddes A.M. Cefpodoxime proxetil in the treatment of lower respiratory tract infections. Drugs. 1991;42(Suppl. 3):34-40. DOI: 10.2165/00003495-199100423-00008
  • 29. Periti P., Novelli A., Schildwachter G., Schmidt-Gayk H., Ryo Y., Zuck P. Efficacy and tolerance of cefpodoxime proxetil compared with co-amoxiclav in the treatment of exacerbations of chronic bronchitis. J Antimicrob Chemother. 1990;26(Suppl. E):63-69. DOI: 10.1093/jac/26.suppl_e.63
  • 30. Lezama M.A.S. Comparison of cefpodoxime proxetil and amoxicillin/clavulanic acid in the treatment of elderly patients with acute exacerbations of chronic bronchitis and pneumonia. Curr Ther Res. 1996;57(13):97-102. DOI: 10.1016/S0011-393X(96)80106-8
  • 31. Ministry of Healthcare of Russian Federation. Clinical recommendations. Chronic bronchitis. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/655_1. Accessed October 01, 2023. Russian.
  • 32. Bittner M.J., Toney J.F., Eleftheriou P., Ribner B.S. Randomized, double-blind comparison of oral cefpodoxime and parenteral ceftriaxone in hospitalized adults with community-acquired pneumonia. Available at: https://api.semanticscholar.org/CorpusID:9144207.
  • 33. Zuck P., Rio Y., Ichou F. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. J Antimicrob Chemother. 1990;26(Suppl. E):71-77. DOI: 10.1093/jac/26.suppl_e.71
  • 34. Hendrickson J.R., North D.S. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patents from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother. 1995;29(6):561-565. DOI: 10.1177/106002809502900601
  • 35. Balfour J.A., Benfield P. Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections Pharmacoeconomics. 1996;10(2):164-178. DOI: 10.2165/00019053-199610020-00008
  • 36. IQVIA retail audit monitoring system data for 2022-2023, as of 09.12.2023. Available at: https://reports.solutions.iqvia.com. Accessed December 12, 2023. Russian.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared